Pembrolizumab (anti-PD-1)

Catalog No.A2005        Batch: A200506

Print

Technical Data

CAS No. 1374853-91-4
Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 6.1mg/ml
Endotoxin Level ＜1EU/mg

Biological Activity

Description Pembrolizumab (anti-PD-1) is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
Targets
PD-1 [1]
(Cell-free assay)
In vitro

The level of LDH and apoptosis are significantly higher in those treated with dexamethasone plus PD1 inhibitor pembrolizumab than other groups.[1]
In vivo

Pembrolizumab and dexamethasone synergistically suppress tumor growth of pancreatic cancer in vivo.[1]

Protocol (Only for Reference)

Cell Assay:

  • Cancer cells were incubated with dexamethasone for 48 h followed by co-cultured with PBMCs with effector/target ratio of 10:1 and the addition of PD1 inhibitor (pembrolizumab; 5 μg/mL) for another 48 h. LDH level was detected.
Animal Study:

  • Animal Models: Immune reconstituted NOD/SCID mice model
    Dosages: 5 mg/kg
    Administration: i.v.
    Reference: [1]
     

Selleck's Pembrolizumab (anti-PD-1) has been cited by 73 publications

IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer [ Mol Cancer, 2025, 24(1):80] PubMed: 40091029
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer [ Nat Commun, 2025, 16(1):2374] PubMed: 40064880
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T-cells in uveal melanoma patients [ J Clin Invest, 2025, e181464] PubMed: 40311102
In situ and dynamic screening of extracellular vesicles as predictive biomarkers in immune-checkpoint inhibitor therapies [ J Nanobiotechnology, 2025, 23(1):411] PubMed: 40457452
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients [ Cell Death Dis, 2025, 16(1):286] PubMed: 40221409
Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication [ Cell Rep, 2025, 44(5):115584] PubMed: 40244846
Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity [ Commun Biol, 2025, 8(1):621] PubMed: 40240529
Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity [ BMC Immunol, 2025, 26(1):4] PubMed: 39844069
Antigenic cancer persister cells survive direct T cell attack [ bioRxiv, 2025, 2025.03.14.643359] PubMed: 40166148
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [ Nat Med, 2024, 10.1038/s41591-024-02824-y] PubMed: 38374347

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.